The Pharming Group Securities Case: Who Knew the Old Drug Was Dying, and When?

The CEO of Pharming Group told investors in November 2025 that he "cannot comment on how sebetralstat is doing" and insisted his company's legacy drug wasn't under competitive pressure from it. Nine months later, that legacy drug's sales were down 10% for the second consecutive quarter, full-year guidance was slashed by roughly $30 million, and the stock fell 22% in a single day.

That is the timeline multiple investor-law firms are now circling. The question they're testing is the standard one in these cases: was the CEO's statement forward-looking optimism that later proved wrong, or was it a present-fact claim that was already false when it was made?

-

Pharming Group is a Dutch-incorporated biotech company (it trades on the NASDAQ) that makes drugs for hereditary angioedema, a rare immune disorder. Its core franchise is RUCONEST, an injectable therapy that has been on the market for years. Its newer product, Joenja, is also an HAE treatment but delivered differently - and it grew 40% in the second quarter to $17.9 million. Joenja is the growth story. RUCONEST is the cash cow that stopped growing.

The plumbing of the alleged securities problem is straightforward. On the November 2025 earnings call, CEO Fabrice Chouraqui was asked about sebetralstat, a new oral HAE therapy from a competitor. His response - "We don't see RUCONEST competing head-to-head with sebetralstat" - is the kind of thing CEOs say constantly. It sounds reassuring, and in the abstract, it might have been true at the time.

Then Q1 2026 arrived. RUCONEST revenue fell 15% year-over-year to $58.4 million. Total revenue dropped 8%. The stock fell roughly 19%. And yet - here is the part that matters - on the May 7, 2026 call, Chouraqui reaffirmed full-year revenue guidance of $405 million to $425 million, representing 8% to 13% growth. The company attributed the Q1 decline to "anticipated U.S. inventory drawdowns" and a planned exit from non-U.S. markets, and the CEO said RUCONEST had "retained the overwhelming majority of patients."

The market was not convinced. The stock still fell in May. But it wasn't until July 30, 2026, that the full picture broke.

Q2 revenue came in at $90.2 million, down 3% year-over-year. RUCONEST sales fell 10% to $72.3 million. Joenja was fine - up 40% - but it's too small to carry the ship yet. Diluted EPS was $0.002 versus $0.006 a year prior. And the full-year guidance was cut to $375–$395 million, roughly $30 million below the prior midpoint and below analyst consensus of about $419 million.

The stock dropped 22% in a single session. As of today, it's trading around $10.54, down roughly 40% year-to-date and about 32% over the last four months.

-

The legal theory - as announced by Levi & Korsinsky, the firm most actively publicizing this case - runs along two tracks. First: whether the November 2025 statement about competitive dynamics was misleading. Second: whether the May 2026 reaffirmation of guidance was misleading given what management already knew (or should have known) from the Q1 results.

The second track is the more interesting one. In May, the company itself had just reported a 15% RUCONEST decline. The CEO's own explanation - inventory drawdowns, non-U.S. exits - only covers part of that drop. The rest of the decline had to come from something else: fewer patients, smaller volumes, competitive erosion, or a mix. And yet the guidance was maintained, implying that H1 softness would be more than offset by H2.

The simplest model is this: if RUCONEST was already down 15% in Q1 and the company's explanation didn't fully account for the decline, then maintaining an 8–13% full-year growth target required assuming a recovery that may not have been grounded in internal data. If internal data showed patient attrition or competitive pressure that wasn't disclosed, that's the securities claim. If the recovery assumption was just wrong - if the company genuinely believed H2 would rebound and was simply surprised - that's bad forecasting, not fraud.

In practice, these cases almost always turn on internal documents. Did management have data showing RUCONEST patient loss to sebetralstat or other competitors? Was that data discussed internally before the May call? If the answer to both is yes, the case has legs. If the company's internal view was that Q1 was a one-off timing event and H2 would normalize, the case is weaker - not nonexistent, but weaker.

The gap between the May reaffirmation and the July cut is about $30 million at the midpoint. That's roughly 7% of the company's revenue base. It's not a tiny number, but it's also not a revelation that the business was collapsing. RUCONEST in Q2 ($72.3M) was higher than Q1 ($58.4M), which the company would argue shows normalization. The Q2 quarter was bigger than Q1. What changed was the trajectory - two quarters of year-over-year decline suggests the headwinds are structural, not one-off.

-

This is basically the same machine that runs through dozens of these securities cases every year. A company makes an optimistic statement. The next quarter or two disappoints. Guidance gets cut. The stock falls. Law firms publish press releases announcing "investigations" - which means they're evaluating whether to file a class action, not that the SEC has found wrongdoing.

The press releases themselves are a mechanism. Levi & Korsinsky (operating under the SueWallSt brand) is an investor-law firm that routinely publishes these announcements. They are free for shareholders to participate in, handled on contingency, and the firm's job is to find enough plaintiffs to make a class action viable. The fact that multiple firms are investigating the same stock doesn't mean the case is stronger; it means the stock drop was large enough to attract attention.

The actual SEC hasn't announced anything here. These are private-law-firm investigations. That distinction matters because the bar for a shareholder class action is different from the bar for an SEC enforcement action.

-

The structural implication for the reader: Pharming Group is a company where the old drug is bleeding and the new drug isn't big enough yet to replace it. Joenja's 40% growth is real, but from a prior-year base of about $12.8 million, that's $5.1 million of growth. RUCONEST's 10% decline is $8.0 million of loss. The net is negative. The guidance cut reflects arithmetic, not accounting trickery.

Whether management should have seen the decline coming earlier is the disclosure question. Whether the business model works is the investment question. They're the same data but different machines.

The stock is down 40% for the year and trading roughly half of its 52-week high of $21.34. At this point, the case for the stock depends on Joenja scaling fast enough to absorb RUCONEST's decline - and on whether the competitive landscape for HAE therapies is still open or whether Pharming is losing its position in a market it helped create.

The securities case, if it proceeds, will turn on internal emails, sales data, and whether the CEO's November optimism was honest conviction or a statement he knew he couldn't support. That's the kind of question that's usually answered months from now, after document production. For now, the machine is in its earliest phase: law firms casting a net, shareholders gathering brokerage statements, and a company that needs H2 to prove the H1 softness was temporary.

The compressed version: the guidance cut was $30 million below where management told investors it would be less than three months earlier. The decline was concentrated in a product whose competitive position the CEO had publicly denied was under pressure. Whether that's fraud or bad forecasting is the open question - but either way, the market has already voted.